Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Kathleen R Whiteman"'
Autor:
Taylor L Hickman, Eugene Choi, Kathleen R Whiteman, Sujatha Muralidharan, Tapasya Pai, Tyler Johnson, Avani Parikh, Taylor Friedman, Madaline Gilbert, Binzhang Shen, Luke Barron, Kathleen E McGinness, Seth A Ettenberg, Greg T Motz, Glen J Weiss, Amy Jensen-Smith
Publikováno v:
PLoS ONE, Vol 17, Iss 5, p e0266980 (2022)
PurposeThe solid tumor microenvironment (TME) drives T cell dysfunction and inhibits the effectiveness of immunotherapies such as chimeric antigen receptor-based T cell (CAR T) cells. Early data has shown that modulation of T cell metabolism can impr
Externí odkaz:
https://doaj.org/article/e9bfd0d7932a41a6b4376dcb7b3a2440
Autor:
Victor S Goldmacher, Charlene A Audette, Yinghua Guan, Eriene-Heidi Sidhom, Jagesh V Shah, Kathleen R Whiteman, Yelena V Kovtun
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0117523 (2015)
The microtubule-targeting maytansinoids accumulate in cells and induce mitotic arrest at 250- to 1000-fold lower concentrations than those required for their association with tubulin or microtubules. To identify the mechanisms of this intracellular a
Externí odkaz:
https://doaj.org/article/e72da5b89d77491ea5ee1090969d22e4
Autor:
Ravi V.J. Chari, John M. Lambert, Victor Goldmacher, Jan Pinkas, Rajeeva Singh, Holly A. Modafferi, Alan Wilhelm, Michele F. Mayo, Charlene A. Audette, Erin K. Maloney, Katie E. Archer, Emily E. Reid, Yelena Kovtun, Kathleen R. Whiteman, Wei Li, Nathan E. Fishkin, Michael L. Miller
Comparative in vitro potency of IGNs with a diimine (1), monoimine (3), and diamine (2) towards hematologic and solid tumor cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060b3dbf22b8e72bcb6de9a2cf408c75
https://doi.org/10.1158/1535-7163.22508386
https://doi.org/10.1158/1535-7163.22508386
Autor:
Ravi V.J. Chari, John M. Lambert, Victor Goldmacher, Jan Pinkas, Rajeeva Singh, Holly A. Modafferi, Alan Wilhelm, Michele F. Mayo, Charlene A. Audette, Erin K. Maloney, Katie E. Archer, Emily E. Reid, Yelena Kovtun, Kathleen R. Whiteman, Wei Li, Nathan E. Fishkin, Michael L. Miller
Synthesis of IGNs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4d0a62fe9e14ab872c4a228aa07177
https://doi.org/10.1158/1535-7163.22508392.v1
https://doi.org/10.1158/1535-7163.22508392.v1
Autor:
Ravi V.J. Chari, John M. Lambert, Victor Goldmacher, Jan Pinkas, Rajeeva Singh, Holly A. Modafferi, Alan Wilhelm, Michele F. Mayo, Charlene A. Audette, Erin K. Maloney, Katie E. Archer, Emily E. Reid, Yelena Kovtun, Kathleen R. Whiteman, Wei Li, Nathan E. Fishkin, Michael L. Miller
Figure S1. Comparison of the rate of adduct formation of the indolinobenzodiazepine dimer 6 and the pyrrolobenzodiazepine dimer SJG-136 with dsDNA prepared from annealing of single strand DNA 3'-TATAGATCTATA-5'. Figure S2. A, In vitro potency of anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8679b5302ba5296c6d41da8fcd17ee
https://doi.org/10.1158/1535-7163.22508395
https://doi.org/10.1158/1535-7163.22508395
Autor:
John M. Lambert, Thomas Chittenden, Victor S. Goldmacher, Jan Pinkas, Robert J. Lutz, Gillian Payne, Alyssa LaBelle, Daniel Tavares, Rajeeva Singh, Xiuxia Sun, Laura M. Bartle, Kathleen R. Whiteman, Olga Ab
Supplemental Figure S1. Activity of anti-FRα clones in an indirect cytotoxicity assay. Supplemental Figure S2. The antigen-dependent cell-mediated cytotoxic activity of M9346A antibody against Igrov-1 cells. Supplemental Figure S3. Activity of the M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b36735412d2d96a25eefaa5052db13
https://doi.org/10.1158/1535-7163.22502020
https://doi.org/10.1158/1535-7163.22502020
Autor:
Tyler B. Johnson, Taylor Friedman, Eugene Choi, Madaline Gilbert, Barron Luke, Sujatha Muralidharan, Tapasya Pai, Kathleen E. McGinness, Taylor Hickman, Seth Ettenberg, Amy Jensen-Smith, Kathleen R. Whiteman, Binzhang Shen, Greg Motz, Avani Parikh, Glen J. Weiss
PurposeThe solid tumor microenvironment (TME) drives T cell dysfunction and inhibits the effectiveness of immunotherapies such as chimeric antigen receptor-based T cell (CAR T) cells. Early data has shown that modulation of T cell metabolism can impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdc6eb317e873444c9c4a90e0f6bd32d
https://doi.org/10.1101/2021.11.17.469041
https://doi.org/10.1101/2021.11.17.469041
Autor:
Yelena Kovtun, Katharine C. Lai, Kathleen R. Whiteman, Gerrit Jan Schuurhuis, Gert J. Ossenkoppele, P. Noordhuis, Gregory E. Jones, Jan Pinkas, Eunice S. Wang, Lauren Harvey, Sharlene Adams, Callum M. Sloss, Scott Portwood, Krystal Watkins
Publikováno v:
Kovtun, Y, Noordhuis, P, Whiteman, K R, Watkins, K, Jones, G E, Harvey, L, Lai, K C, Portwood, S, Adams, S, Sloss, C M, Schuurhuis, G J, Ossenkoppele, G, Wang, E S & Pinkas, J 2018, ' IMGN779, a Novel CD33-targeting antibody–drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML ', Molecular Cancer Therapeutics, vol. 17, no. 6, pp. 1271-1279 . https://doi.org/10.1158/1535-7163.MCT-17-1077
Molecular Cancer Therapeutics, 17(6), 1271-1279. American Association for Cancer Research Inc.
Molecular Cancer Therapeutics, 17(6), 1271-1279. American Association for Cancer Research Inc.
The myeloid differentiation antigen CD33 has long been exploited as a target for antibody-based therapeutic approaches in acute myeloid leukemia (AML). Validation of this strategy was provided with the approval of the CD33-targeting antibody–drug c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce88f864a4a7040961017e2c236c8f73
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048093057&origin=inward
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048093057&origin=inward
Autor:
Daniel Tavares, Nicholas C. Yoder, Shan Jin, Wayne C. Widdison, Lintao Wang, Hans K. Erickson, Kathleen R. Whiteman, Molly A. McShea, Chen Bai, Erin K. Maloney, Olga Ab, Thomas A. Keating, John M. Lambert, Sharon D. Wilhelm, Alan Wilhelm
Publikováno v:
Molecular pharmaceutics. 16(9)
Antibody-drug conjugates are an emerging class of cancer therapeutics constructed from monoclonal antibodies conjugated with small molecule effectors. First-generation molecules of this class often employed heterogeneous conjugation chemistry, but ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aae682bfb61d0c1b588a5fc0e0b3de9
https://pubmed.ncbi.nlm.nih.gov/31287952
https://pubmed.ncbi.nlm.nih.gov/31287952
Autor:
John M. Lambert, E. Erica Hong, Hans K. Erickson, Veronique Blanc, Robert J. Lutz, Gregory T. Jones, Yelena Kovtun, Kathleen R. Whiteman
Publikováno v:
Molecular Pharmaceutics. 12:1703-1716
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b3865fb0ead8f9843251b4240f2b48
https://doi.org/10.1021/acs.molpharmaceut.5b00175
https://doi.org/10.1021/acs.molpharmaceut.5b00175